A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) plus Carboplatin-Paclitaxel versus Placebo plus Carboplatin-Paclitaxel in Patients with Recurrent or Primary Advanced Endometrial Cancer (RUBY) - RUBY

TESARO, Inc.0 个研究点目标入组 470 人开始时间: 2020年3月16日最近更新: 2020年7月6日

适应症

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方: TESARO, Inc.
入组人数: 470

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional clinical trial of medicinal product

入排标准

性别: Female

入选标准

•1. Female subject at least 18 years of age, who is able to understand the study procedures and agrees to participate in the study by providing written informed consent.
•2. Subject has histologically or cytologically proven endometrial cancer with recurrent or advanced disease.
•3. Subject must provide adequate tumor tissue sample at Screening for MSI status testing.
•4. Subject must have primary Stage III or Stage IV disease or first recurrent endometrial cancer with a low potential for cure by radiation therapy or surgery alone or in combination, and meet at least one of the following criteria:
•a. Subject has primary Stage IIIA to IIIC1 disease with presence of evaluable or measurable disease per RECIST v.1.1 based on Investigator’s assessment. Lesions
•that are equivocal or can be representative of postoperational change should be biopsied and confirmed for the presence of tumor.
•b. Subject has primary Stage IIIC1 disease with carcinosarcoma, clear cell, serous, or mixed histology (containing = 10% carcinosarcoma, clear cell, or serous histology) regardless of presence of evaluable or measurable disease on imaging.
•c. Subject has primary Stage IIIC2 or Stage IV disease.
•d. Subject has first recurrent disease and is chemotherapy naïve.
•e. Subject has received prior neo-adjuvant/adjuvant systemic chemotherapy and had a recurrence or PD = 6 months after completing treatment (first recurrence).
•5. Subject has an ECOG performance status of 0 or 1.
•6. Subject has adequate organ function, defined as follows:
•a. Absolute neutrophil count = 1,500 cells/µL b. Platelets = 100,000 cells/µL c. Hemoglobin = 9 g/dL or = 5.6 mmol/L d. Serum creatinine = 1.5× upper limit of normal (ULN) or calculated creatinine clearance = 50 mL/min using the Cockcroft-Gault equation for subjects with creatinine levels > 1.5× institutional ULN
•e. Total bilirubin = 1.5× ULN and direct bilirubin = 1× ULN
•f. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) = 2.5× ULN unless liver metastases are present, in which case they must be = 5× ULN
•g. International normalized ratio or prothrombin time (PT) =1.5× ULN and activated partial thromboplastin time =1.5× ULN. Subjects receiving anticoagulant therapy must have a PT or partial thromboplastin within the therapeutic range of intended use of anticoagulants.
•7. Subject must have a negative serum pregnancy test within 72 hours of the first dose of study medication, unless they are of nonchildbearing potential. Nonchildbearing potential is defined as follows:
•a. Postmenopausal (a woman who is = 45 years of age and has not had menses for > 1 year).
•b. A follicle-stimulating hormone value in the postmenopausal range upon screening evaluation if amenorrheic for < 2 years without a hysterectomy and oophorectomy
•c. Posthysterectomy, postbilateral oophorectomy, or posttubal ligation.
•- Documented hysterectomy or oophorectomy must be confirmed with medical records of the actual procedure or confirmed by an ultrasound, MRI, or CT scan.
•- Tubal ligation must be confirmed with medical records of the actual procedure; otherwise, the subject must fulfill the criteria in Inclusion Criterion 8.
•- Information must be captured appropriately within the site’s source documents.
•8. Subjects of childbearing potential must be non-pregnant (see criterion above) and non-breast feeding, and must
•agree to use at least 1 highly effective form of contraception or must not be heterosexually active starting with the Screening Visit through

排除标准

•1. Subject has received neo-adjuvant/adjuvant systemic chemotherapy for primary Stage III or IV disease and:
•a. has not had a recurrence or PD prior to entering the study OR
•b. has had a recurrence or PD within 6 months of completing chemotherapy treatment prior to entering the study Note: Low-dose cisplatin given as a radiation sensitizer or hormonal therapies do not exclude subjects from study participation.
•2. Subject has had > 1 recurrence of endometrial cancer.
•3. Subject has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent.
•4. Subject has received prior anticancer therapy (chemotherapy, targeted therapies, hormonal therapy, radiotherapy, or immunotherapy) within 21 days or < 5 times the half-life of the most recent therapy prior to Study Day 1, whichever is shorter.
•5. Subject has a concomitant malignancy, or subject has a prior non-endometrial invasive malignancy who has been disease-free for < 3 years or who received any active treatment in the last 3 years for that malignancy. Non-melanoma skin cancer is allowed.
•6. Subject has known uncontrolled central nervous system metastases, carcinomatosis meningitis, or both. Note: Subjects with previously treated brain metastases may participate provided they are stable (without evidence of PD by imaging [using the identical imaging modality for each assessment, either MRI or CT scan] for at least 4 weeks prior to the first dose of study treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and have not been using steroids for at least 7 days prior to study treatment. Carcinomatous meningitis precludes a subject from study participation regardless of clinical stability.
•7. Subject has a known history of human immunodeficiency virus (HIV; HIV 1/2 antibodies).
•8. Subject has known active hepatitis B (eg, hepatitis B surface antigen reactive) or hepatitis C (eg, hepatitis C virus ribonucleic acid [qualitative] is detected).
•9. Subject has an active autoimmune disease that has required systemic treatment in the past 2 years. Replacement therapy is not considered a form of systemic therapy (eg, thyroid hormone or insulin)
•10. Subject has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of systemic immunosuppressive therapy within 7 days prior to the first dose of study treatment.
•11. Subject has not recovered (ie, to Grade = 1 or to baseline) from cytotoxic therapy-induced AEs. Note: Subjects with Grade = 2 neuropathy, Grade = 2 alopecia, or Grade = 2 fatigue are an exception to this criterion and may qualify for the study.
•12. Subject has not recovered adequately from AEs or complications from any major surgery prior to starting therapy.
•13. Subject has a known hypersensitivity to carboplatin, paclitaxel, or dostarlimab components or excipients.
•14. Subject is currently participating and receiving study treatment or has participated in a study of an investigational agent and received study treatment or used an investigational device within 4 weeks of the first dose of treatment.
•15. Subject is considered a poor medical risk due to a serious, uncontrolled medical disorder, nonmalignant systemic disease, or active infection requiring systemic therapy. Specific examples include, but are not limited to, active, noninfectious pneumonitis; uncontrolled ventricular arrhythmia; recent (within 90 days) myocardial infarction; uncontrolled major seizure disorder; unsta

研究者

发起方

TESARO, Inc.

相似试验

进行中（未招募）

1 期

A study to determine whether the addition of Dostarlimab (TSR-042) delays recurrence of advanced endometrial cancerRecurrent or primary advanced (Stage III or IV) endometrial cancerMedDRA version: 21.0Level: PTClassification code 10014740Term: Endometrial cancer stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 21.0Level: PTClassification code 10014741Term: Endometrial cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2019-001576-11-FITESARO, Inc.740

进行中（未招募）

1 期

EUCTR2019-001576-11-ITTESARO, INCORPORATED470

进行中（未招募）

1 期

EUCTR2019-001576-11-ESTESARO, Inc.740

进行中（未招募）

1 期

EUCTR2019-001576-11-BETESARO, Inc.740

进行中（未招募）

1 期

EUCTR2019-001576-11-GRTESARO, Inc.740